Aethlon Medical (NASDAQ:AEMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report report published on Tuesday morning. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright decreased their price target on shares of Aethlon Medical from $10.00 to $7.00 and set a “buy” rating for the company in a report on Monday, June 24th.

Aethlon Medical Price Performance

Shares of AEMD opened at $0.38 on Tuesday. Aethlon Medical has a one year low of $0.24 and a one year high of $2.35. The company has a 50-day moving average of $0.41 and a two-hundred day moving average of $0.66. The stock has a market cap of $5.25 million, a price-to-earnings ratio of -0.08 and a beta of 1.74.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.10. During the same quarter last year, the firm earned ($1.30) earnings per share. Analysts anticipate that Aethlon Medical will post -1.1 earnings per share for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.